Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBP-418 in Limb Girdle Muscular Dystrophy 2I
NCT05775848Phase 3Active, not recruiting
- Sponsor
- ML Bio Solutions
- Start
- May 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of ribitol in limb-girdle muscular dystrophy type 2I (LGMD2I), sponsored by ML Bio Solutions. Started May 2023; status: active, not recruiting.
02
Drugs
ribitol
03
Conditions
limb-girdle muscular dystrophy type 2I (LGMD2I)
Beyond the preview
Go deeper on NCT05775848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775848.